This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive

This study has been completed.
Sponsor:
Collaborator:
Major Science and Technology Special Project of China Eleventh Five-year
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01086085
First received: March 11, 2010
Last updated: November 1, 2016
Last verified: November 2016
  Purpose
This open-label, multi-center study will evaluate the effect on the quantitative HBsAg reduction of peginterferon alfa-2a [PEGASYS] in patients with HBeAg positive chronic hepatitis B. Patients will receive PEGASYS 180 mcg sc once weekly. After 24 weeks of treatment, rapid responders will receive another 24 weeks of treatment. After 24 weeks of treatment, slow responders will be randomized to another 24 or 72 weeks of PEGASYS monotherapy, or to 72 weeks PEGASYS plus 36 weeks adefovir (10 mg, po once daily, starting from week 29 of PEGASYS treatment). The anticipated time on study drug is >2 years.

Condition Intervention Phase
Hepatitis B, Chronic Drug: Adefovir Drug: peginterferon alfa-2a [PEGASYS] Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Study on Optimizing the Treatment in HBeAg Positive CHB Patients With Response Guide Treatment (RGT) Method.

Resource links provided by NLM:


Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Efficacy: Quantitative HBsAG reduction (proportion of patients with HBsAG reduction) [ Time Frame: Weeks 72, 96, 120 ]

Secondary Outcome Measures:
  • Proportion of patients achieving HBeAG seroconversion and HBV DNA </=100000 copies/ml [ Time Frame: Weeks 24, 48, 72, 96, 120 ]
  • Safety: Adverse Events [ Time Frame: From baseline to Week 120 ]

Enrollment: 265
Study Start Date: April 2010
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A Drug: peginterferon alfa-2a [PEGASYS]
Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
Experimental: B Drug: peginterferon alfa-2a [PEGASYS]
Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
Experimental: C Drug: peginterferon alfa-2a [PEGASYS]
Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
Experimental: D Drug: Adefovir
Adefovir 10 mg po once daily for 36 weeks
Drug: peginterferon alfa-2a [PEGASYS]
Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients >/=18 years of age
  • HBeAg positive chronic hepatitis B
  • Compensated liver disease

Exclusion Criteria:

  • Patients who had previously received treatment of drugs with activity against HBV within 6 months prior to study start
  • Antiviral, anti-neoplastic or immunomodulatory treatment
  • Co-infection with active hepatitis A, hepatitis C, hepatitis D, or HIV
  • Evidence of decompensated liver disease
  • Chronic liver disease other than viral hepatitis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01086085

Locations
China
Beijing, China, 100011
Beijing, China, 100034
Beijing, China, 100044
Beijing, China, 100050
Changchun, China, 130021
Guangzhou, China, 510515
Shanghai, China, 200025
Shanghai, China, 200040
Shanghai, China, 200433
Wuhan, China, 430030
Xi'an, China, 710038
Sponsors and Collaborators
Hoffmann-La Roche
Major Science and Technology Special Project of China Eleventh Five-year
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01086085     History of Changes
Other Study ID Numbers: ML22266
Study First Received: March 11, 2010
Last Updated: November 1, 2016

Additional relevant MeSH terms:
Hepatitis
Hepatitis B
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepadnaviridae Infections
DNA Virus Infections
Virus Diseases
Hepatitis, Viral, Human
Hepatitis, Chronic
Peginterferon alfa-2a
Interferon-alpha
Adefovir
Adefovir dipivoxil
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents

ClinicalTrials.gov processed this record on July 21, 2017